Most longevity claims cite evidence. Most of that evidence is misrepresented, misunderstood, or misapplied. Here is a structured framework for evaluating any longevity intervention claim.
The longevity medicine space has a evidence problem that is distinct from most of medicine. It is not that evidence is absent — it is that evidence of wildly different quality is presented with equal confidence, and the distinction between them is systematically obscured.
A physician evaluating a longevity intervention claim needs a structured framework that can be applied consistently across very different evidence types — from single-case reports to multinational Phase III trials. The key variables are: study design, sample characteristics, endpoint type, effect size and confidence interval, duration, replication, and the distinction between association and causation.
The single most important question in evaluating a longevity claim is: what was the endpoint? Hard endpoints — all-cause mortality, cardiovascular death, incident dementia, cancer — provide direct evidence about longevity outcomes. Surrogate endpoints — biomarkers, epigenetic clock scores, inflammatory markers, mitochondrial gene expression — provide mechanistically plausible proxies that may or may not track with hard outcomes. The longevity supplement industry systematically conflates these two categories. A compound that reduces an inflammatory marker has not been shown to extend lifespan. These are different claims.
A single positive RCT is not evidence of efficacy — it is a hypothesis-generating finding that requires replication. Many longevity supplement claims rest on single small trials that have not been independently replicated. The Interventions Testing Program has demonstrated that many longevity interventions that appear promising in initial studies fail to replicate under rigorous multi-site testing. Replication in independent laboratories and populations is essential before any intervention moves from Emerging to Moderate tier.
Evaluating longevity claims requires asking four questions in order: (1) What was the endpoint — hard outcome or surrogate? (2) What was the study design — RCT, observational, or in vitro? (3) Has the finding been independently replicated? (4) What are the confidence intervals and is the effect size clinically meaningful? Geroevidence applies this framework systematically to every intervention in the database.
This information is provided for educational reference only and does not constitute medical advice or a treatment recommendation.